Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome

Medicine (United States)

Volumn 96, Issue 11, 2017, Pages

  Gustavsen, Alice ^a   Skattum, Lillemor ^b   Bergseth, Grethe ^c   Lorentzen, Bjorg ^d   Floisand, Yngvar ^d   Bosnes, Vidar ^d   Mollnes, Tom Eirik ^a,c,e   Barratt Due, Andreas ^a,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF TROMSØ   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

antiphospholipid syndrome; complement; eculizumab; pregnancy

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C8; COMPLEMENT FACTOR; ECULIZUMAB; COMPLEMENT; MONOCLONAL ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD SAMPLING; CASE REPORT; CESAREAN SECTION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; COMPLEMENT LECTIN PATHWAY; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; INFANT; NEWBORN; OBSTETRIC DELIVERY; PATHOGENESIS; PLACENTAL TRANSFER; PREMATURITY; PRIORITY JOURNAL; PUERPERIUM; UMBILICAL ARTERY; UMBILICAL VEIN; YOUNG ADULT; ANTAGONISTS AND INHIBITORS; METABOLISM; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPHOSPHOLIPID SYNDROME; CESAREAN SECTION; COMPLEMENT C5; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; YOUNG ADULT;

EID: 85016000707     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000006338     Document Type: Article

References (17)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Allen KL, Fonseca FV, Betapudi V, et al. A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood 2012;119:884-93.
3. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002;195:211-20.
4. Romay-Penabad Z, Carrera Marin AL, Willis R, et al. Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus 2014;23:1324-6.
5. Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013;368:1033-44.
6. Gomez-Puerta JA, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: diagnosis and management in pregnancy. Clin LabMed 2013;33:391-400.
7. Cervera R, Rodriguez-Pinto I. Catastrophic antiphospholipid syndrome: task force report summary. Lupus 2014;23:1283-5.
8. Barratt-Due A, Floisand Y, Orrem HL, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology (Oxford) 2016;55:1337-9.
9. Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 2014;93:e143.
10. Rodriguez-Pintó I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: the current management approach. Best Pract Res Clin Rheumatol 2016;30:239-49.
11. Ruffatti A, Salvan E, Del Ross T, et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost 2014;112:727-35.
12. Hallstensen RF, Bergseth G, Foss S, et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology 2015;220:452-9.
13. Kelly RJ, Hochsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015; 373:1032-9.
14. McGreal EP, Hearne K, Spiller OB. Off to a slow start: underdevelopment of the complement system in term newborns is more substantial following premature birth. Immunobiology 2012;217: 176-86.
15. Bramham K, Hunt BJ, Germain S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus 2010;19:58-64.
16. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014;13:685-96.
17. Dmytrijuk A, Robie-Suh K, Cohen MH, et al. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Oncologist 2008;13:993-1000.